COMP vs NBIX · rev $5.63B vs P/E 45, rev $2.36B
Compass Inc (COMP) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Compass Inc (COMP) is a real estate services company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported COMP revenue for 2024-12-31 was $5.63B. Net income was -$154.5M. Revenue was up 15.2% from 2023-12-31 to 2024-12-31. COMP currently screens at market cap $3.35B.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
COMP currently screens at market cap $3.35B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the COMP and NBIX stock pages for the full models.
Not investment advice.